Teva

Teva Pharmaceutical Industries Limited is a global pharmaceutical company headquartered in Petach Tikva, Israel, established in 1901. It specializes in the development, manufacture, marketing, and distribution of generic and proprietary branded medications, as well as active pharmaceutical ingredients. Teva is recognized as the leading manufacturer of generic drugs worldwide, with approximately half of its sales generated in North America, alongside a strong presence in Europe and other markets. The company's diverse portfolio includes specialty medicines in key therapeutic areas such as central nervous system disorders, respiratory conditions, and oncology. Notable products include Copaxone for multiple sclerosis, AJOVY for migraine prevention, ProAir and QVAR for asthma, and various oncology treatments. Teva also engages in innovative research and offers contract manufacturing services, contributing to one of the most complex supply chains in the pharmaceutical industry.

Edward Barger

Senior Manager, Investor Relations

Sven Dethlefs

Executive Vice President, Global Marketing and Portfolio

Kevin Mannix

Senior Vice President, Investor Relations

Michael McClellan

Executive Vice President and Chief Financial Officer

Ran Meir

Vice President, Investor Relations

Kare Schultz

President and Chief Executive Officer

21 past transactions

Heptares Therapeutics

Venture Round in 2017
Heptares Therapeutics Ltd. is a clinical-stage drug discovery company based in Welwyn Garden City, United Kingdom, specializing in the development of novel small-molecule medicines that target G protein-coupled receptors (GPCRs), a significant family of druggable targets associated with various human diseases. Founded in 2007, Heptares has pioneered a proprietary technology for creating purified, stabilized, and functional GPCRs, known as StaRs (Stabilised Receptors), which addresses a key challenge in drug development. The company employs advanced techniques such as structure-based drug design, X-ray crystallography, surface plasmon resonance, and fragment screening to discover new chemical entities and antibodies. Heptares has established strategic collaborations with notable entities, including Pfizer, Kymab, PeptiDream, and Jitsubo, to enhance its research and development efforts. As of 2015, the company operates as a subsidiary of Sosei Group Corporation.

Anda

Acquisition in 2016
Anda, Inc. is a wholesale distributor of pharmaceutical products in the United States, supplying a wide range of items including generic, branded, and specialty pharmaceuticals, as well as controlled substances, vaccines, injectables, medical and surgical supplies, and over-the-counter products. The company caters to independent pharmacies, pharmacy chains, hospitals, nursing homes, mail order pharmacies, and physicians' offices, facilitating orders through phone, fax, and online platforms. Founded in 1992 and based in Weston, Florida, Anda, Inc. was previously known as Anda Generics, Inc. and adopted its current name in October 1999. It operates as a subsidiary of Watson Pharmaceuticals, Inc.

Wave Life Sciences

Post in 2015
Wave Life Sciences Ltd. is a clinical stage genetic medicine company that specializes in the design and production of novel stereopure oligonucleotides using its proprietary PRISM platform. Focused on addressing genetic defects, the company develops therapies aimed at reducing the expression of harmful proteins or converting dysfunctional proteins into functional ones. Its primary research areas include neurologic conditions affecting the central and neuromuscular systems. Wave Life Sciences has established research and collaboration agreements with major pharmaceutical companies, including Pfizer and Takeda, to advance its oligonucleotide therapeutics. Founded in 2012, the company is headquartered in Singapore and maintains research facilities in Boston and Japan. The founding scientists, Gregory Verdine and Takeshi Wada, are recognized leaders in the field, contributing their expertise to the development of innovative nucleic acid therapeutics.

Representaciones e Investigaciones Médicas (Rimsa)

Acquisition in 2015
Rimsa, a leading pharmaceutical manufacturing and distribution company in Mexico
CareTRx by Gecko Health is a product and services to improve poor medication adherence for asthma and COPD medication. The company offers a unique solution based on direct monitoring, games and social tools that motivate patients, engage care-givers, and inform clinicians. GeckoCap simplifies adherence to help families and lower costs.

Actavis

Acquisition in 2015
Actavis plc (NYSE: ACT) is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. The Company has global headquarters in Dublin, Ireland and Administrative Headquarters in Parsippany, New Jersey, USA. http://www.allergan.com/products/key-products/generic-products

MicroCHIPS

Venture Round in 2015
Microchips Biotech, Inc. is dedicated to improving the lives of patients by revolutionizing drug delivery. Our proprietary microchip-based implant can store and release precise doses of drugs over months and years. The implant, which is placed under the skin by a trained physician during a simple office procedure using local anesthesia, can be wirelessly activated or deactivated by a physician or patient, without requiring removal. In addition, physicians can wirelessly modify the frequency or dose of the drug to meet the individual needs of each patient.

Auspex Pharmaceuticals

Acquisition in 2015
Auspex Pharmaceuticals is a biopharmaceutical company dedicated to developing and commercializing innovative medicines for orphan diseases. Its pipeline features product candidates aimed at addressing unmet medical needs in conditions such as hyperkinetic movement disorders, which include chorea associated with Huntington’s disease, tardive dyskinesia, and Tourette syndrome. Additionally, the company is involved in creating deuterated analogs of clinically validated drugs, enhancing existing therapies across various therapeutic areas, including respiratory diseases and inflammation. Through its focused approach, Auspex Pharmaceuticals seeks to improve treatment options for patients with specific medical conditions.

Ignyta

Post in 2015
Ignyta is a scientifically-driven biotechnology company catalyzing personalized medicine in autoimmune diseases. Their goal is to revolutionize the quality of biomarkers and tests available to rheumatologists and patients to help them make better informed, more individualized treatment decisions; and to identify truly novel autoimmune disease targets for biopharmaceutical companies to enable the development of precise therapies for patients worldwide. Ignyta was incorporated in 2011 and operates in San Diego, California.

Labrys Biologics

Acquisition in 2014
Labrys Biologics Inc., a company focused on treatments for chronic migraine. Labrys Biologics has acquired worldwide rights to RN-307 from Pfizer Inc. RN-307 is an antibody for the treatment of chronic migraine.

NuPathe

Acquisition in 2014
NuPathe Inc. is a specialty pharmaceutical company dedicated to developing and commercializing innovative therapies for neurological and psychiatric disorders. The company's flagship product is Zecuity, a transdermal system utilizing sumatriptan for the acute treatment of migraines in adults. In addition to Zecuity, NuPathe is advancing a pipeline of product candidates, including NP201, designed for the continuous treatment of Parkinson's disease, and NP202, aimed at the long-term management of schizophrenia and bipolar disorder. Both candidates leverage the company's proprietary Long-Acting Delivery technology, which facilitates extended medication release through biodegradable implants. Founded in 2005 and based in Malvern, Pennsylvania, NuPathe operates as a subsidiary of Teva Pharmaceutical Industries Limited. The company actively seeks partnerships to enhance the commercial potential of its products in the United States and internationally.

MicroDose Therapeutx

Acquisition in 2013
MicroDose Therapeutx is a specialty pharmaceutical company developing next-generation drug delivery products. Most notable are the novel electro-mechanical dry powder inhaler and PolyCap technologies.

Gamida Cell

Series E in 2012
Gamida Cell Ltd. is a clinical-stage biopharmaceutical company focused on developing innovative cell therapies aimed at treating blood cancers and serious blood disorders. The company’s lead product candidate, omidubicel, involves expanded hematopoietic stem cells and T cells, currently undergoing Phase 3 trials for high-risk hematologic malignancies and Phase 1/2 trials for severe aplastic anemia. Additionally, Gamida Cell is advancing GDA-201, a natural killer cell-based immunotherapy, which is in Phase 1/2 studies targeting relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. Founded in 1998 and headquartered in Jerusalem, Israel, Gamida Cell is committed to harnessing the regenerative potential of therapeutic stem cells to address significant unmet medical needs in various diseases.

Cocrystal Discovery

Venture Round in 2011
Cocrystal Discovery is a privately funded biotechnology company developing antiviral therapeutics for human diseases. Cocrystal has breakthrough technologies that enable the creation of first- and best-in-class antivirals. Their mission today is to discover and develop small molecule inhibitors of the viral replication complex.

Cephalon

Acquisition in 2011
Cephalon is a global biopharmaceutical company dedicated to discovering, developing and bringing to market medications to improve the quality of life of individuals around the world. Since its inception in 1987, Cephalon has brought first-in-class and best-in-class medicines to patients in several therapeutic areas. Cephalon has the distinction of being one of the world's fastest-growing biopharmaceutical companies, now among the Fortune 1000 and a member of the S&P 500 Index, employing approximately 4,000 people worldwide. The company sells numerous branded and generic products around the world. In total, Cephalon sells more than 150 products in nearly 100 countries.

Gamida Cell

Series D in 2006
Gamida Cell Ltd. is a clinical-stage biopharmaceutical company focused on developing innovative cell therapies aimed at treating blood cancers and serious blood disorders. The company’s lead product candidate, omidubicel, involves expanded hematopoietic stem cells and T cells, currently undergoing Phase 3 trials for high-risk hematologic malignancies and Phase 1/2 trials for severe aplastic anemia. Additionally, Gamida Cell is advancing GDA-201, a natural killer cell-based immunotherapy, which is in Phase 1/2 studies targeting relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. Founded in 1998 and headquartered in Jerusalem, Israel, Gamida Cell is committed to harnessing the regenerative potential of therapeutic stem cells to address significant unmet medical needs in various diseases.

TransPharma Medical

Series C in 2006
TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transdermal drug delivery technology. Their current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transdermal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1.

BiolineRx

Venture Round in 2005
BioLineRx Ltd. is a clinical-stage biopharmaceutical development company based in Modi’in, Israel, specializing in oncology. The company’s development pipeline includes several therapeutic candidates, such as BL-8040, a peptide aimed at treating solid tumors and hematological malignancies, as well as facilitating stem cell mobilization. Another candidate, AGI-134, is an immuno-oncology agent designed for solid tumors, while BL-5010 is a proprietary applicator intended for the non-surgical removal of skin lesions. BioLineRx has established collaborations with notable organizations, including a partnership with MSD in the cancer immunotherapy field, and agreements with MD Anderson Cancer Center and Genentech Inc. to explore combinations of BL-8040 with existing therapies in clinical studies for pancreatic and other solid tumors. Founded in 2003, BioLineRx is dedicated to addressing unmet medical needs and improving treatment options in oncology.

Proneuron Biotechnologies

Venture Round in 2001
Proneuron Biotechnologies develops spinal cord injury treatments, researches cures for paralysis, and neurological therapies.

Copley Pharmaceutical

Acquisition in 1999
Copley Pharmaceutical is a generic pharmaceutical company that manufactured products for both over-the-counter and prescription sales.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.